Pioneers in Precision Medicine

PellePharm leads the way in applying precision medicine to dermatology.

PellePharm is a biotechnology company committed to targeting rare dermatologic diseases at the source. Founded by world leaders in hedgehog signaling, PellePharm is working to improve the quality of life for those suffering from Gorlin Syndrome and BCCs by providing an easy-to-use topical solution that eliminates the need for regular, painful surgeries.

Leadership

Sanuj Ravindran, M.D.

President, CEO & Director

GERD KOCHENDOERFER, Ph.D.

Senior Vice President & Head of Operations

ALIX ALDERMAN

Vice President, Head of Regulatory Affairs & Market Access

Srikanth Pendyala, M.D.

Vice President of Clinical Development

Joe Suttner

Vice President of Clinical Operations

Sharon Kokubun

Vice President of Finance & Controller

Board of Directors

Sanuj Ravindran, M.D.

President, CEO & Director

JEAN TANG, M.D., Ph.D.

Co-Founder, Medical Advisor & Director

Ervin Epstein, M.D.

Co-Founder, Medical Advisor & Director

Frank McCormick, Ph.D.

Co-Founder of BridgeBio

NEIL KUMAR, Ph.D.

Co-Founder of BridgeBio

Anders Kronborg

CFO of LEO Pharma

Founders

JEAN TANG, M.D., Ph.D.

Co-Founder, Medical Advisor & Director

Ervin Epstein, M.D.

Co-Founder, Medical Advisor & Director

Philip Beachy, Ph.D.

Co-Founder

Investors

Partners

Sanuj Ravindran, M.D.

President, CEO & Director

Sanuj K. Ravindran, M.D. is president and CEO of PellePharm. Dr. Ravindran also serves on the PellePharm Board of Directors, and is CEO-in-Residence with BridgeBio, PellePharm’s parent company.

Dr. Ravindran has more than 15 years of strategic and operational biopharma experience. Previously, he was chief business officer at aTyr Pharma (“LIFE”), a clinical stage rare disease-focused biotechnology company, where he led corporate strategy, financial strategy, business development, and investor relations. Prior to that, Dr. Ravindran was senior vice president of corporate development for The Medicines Company (“MDCO”), where he worked to execute multiple transactions totaling more than $2 billion in potential aggregate value. Previously a practicing physician, Dr. Ravindran began his industry career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund.

Dr. Ravindran is trained in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital. Dr. Ravindran received his B.A. from Northwestern University, his M.D. from Jefferson Medical College and his MBA from the Kellogg School of Management.

Back to Management Team

GERD KOCHENDOERFER, Ph.D.

Senior Vice President & Head of Operations

Gerd has more than 20 years of experience in drug development, operations, quality and program management in the biotech and specialty pharma industry. Prior to joining PellePharm, Gerd helped transform Depomed from a small drug delivery company to a specialty pharma company in the pain and neurology space with over $450 million in annual revenue as the executive team member overseeing the technical operations, project management and quality functions. Previously, Gerd held research and drug development management positions at FibroGen, Inc., and Gryphon Therapeutics. During his time, he led more than a dozen drug development programs ranging from early-stage research to NDA approval and multiple global drug development alliances. He was also part of diligence and deal teams responsible for drug licensing and product acquisition transactions cumulatively valued at over $1.5 billion. Gerd earned his Ph.D. in chemistry from the University of California at Berkeley. He has published more than 25 papers in peer-reviewed literature and holds multiple patents.

Back to Management Team

ALIX ALDERMAN

Vice President, Head of Regulatory Affairs & Market Access

Alix Alderman is vice president of regulatory affairs at PellePharm. Prior to joining PellePharm, Alix led all regulatory aspects of global development and strategy for the rare bone disease programs at Ultragenyx as senior director of regulatory affairs. Prior to Ultragenyx, she served as global regulatory lead and director of global product strategy at Abbott/AbbVie. Previously, she held numerous positions of increasing responsibility at Amylin and InterMune, including regulatory affairs leadership for Amylin’s lipodystrophy, obesity and pramlintide early development and commercial franchise. Alix is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and has served for many years on the TOPRA Board of Directors. She earned her bachelor’s degree in exercise physiology from the University of California at Davis.

Back to Management Team

Srikanth Pendyala, M.D.

Vice President of Clinical Development

Srikanth Pendyala, M.D. is vice president of clinical development at PellePharm. He is a physician-scientist with over 18 years of experience in clinical research, translational sciences and academic medicine. He has a strong background in global clinical development and medical affairs in the inflammatory, respiratory and immunology therapeutic areas. Prior to joining PellePharm, he focused on immunology-inflammation at Genentech/Roche, Merck and Theravance and led the development of a number of molecules from early/late stage clinical trials to regulatory approval. He was involved in multiple NDA filings with approvals and in partnered drug development programs. Additionally, he has published over 30 peer reviewed publications. He has a passion for developing new medicines that make a difference in patients’ lives through scientific excellence holding the highest standards of integrity.

Back to Management Team

Joe Suttner

Vice President of Clinical Operations

Joe Suttner is vice president of clinical operations. Joe brings over 20 years of drug development experience in both the biotech and pharma industries. Prior to joining PellePharm, Joe was part of Dermira’s management team involved in project management, alliance management and NDA/sBLA submission activities. He also participated on acquisition and partnership teams for the company’s first biologic program. Previously, Joe provided leadership to Allergen Research Corporation (ARC), now Aimmune, as Vice President of Clinical Operations. At Aimmune Joe helped establish a network of food allergy centers in collaboration with patient advocacy groups resulting in greater study access for patients worldwide. His experience within the industry has included roles at Amgen, Allergan, Ipsen, and Peplin. Joe earned his BA at California State University Long Beach and his MBA at the University of Liverpool.

Back to Management Team

Sharon Kokubun

Vice President of Finance & Controller

Back to Management Team

Sanuj Ravindran, M.D.

President, CEO & Director

Sanuj K. Ravindran, M.D. is president and CEO of PellePharm. Dr. Ravindran also serves on the PellePharm Board of Directors, and is CEO-in-Residence with BridgeBio, PellePharm’s parent company.

Dr. Ravindran has more than 15 years of strategic and operational biopharma experience. Previously, he was chief business officer at aTyr Pharma (“LIFE”), a clinical stage rare disease-focused biotechnology company, where he led corporate strategy, financial strategy, business development, and investor relations. Prior to that, Dr. Ravindran was senior vice president of corporate development for The Medicines Company (“MDCO”), where he worked to execute multiple transactions totaling more than $2 billion in potential aggregate value. Previously a practicing physician, Dr. Ravindran began his industry career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund.

Dr. Ravindran is trained in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital. Dr. Ravindran received his B.A. from Northwestern University, his M.D. from Jefferson Medical College and his MBA from the Kellogg School of Management.

JEAN TANG, M.D., Ph.D.

Co-Founder, Medical Advisor & Director

Jean Tang, M.D., Ph.D. is co-founder of PellePharm and serves on the PellePharm board of directors. Jean is a practicing dermatologist and associate professor of dermatology at Stanford University. Her research focuses on finding new ways to treat and prevent non-melanoma skin cancer and genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. Jean and her colleagues discovered that hedgehog pathway inhibition could dramatically shrink basal cell carcinoma tumors in patients with Gorlin Syndrome in randomized clinical trials. She has led or co-led four investigator-initiated clinical trials, three of which were focused on basal cell carcinoma treatment or prevention. Jean earned both her M.D. and Ph.D. from Stanford University. She completed her dermatology residency at Stanford and later completed a three-year post-doctorate in mouse genetics at the University of California, San Francisco while simultaneously pursuing formal coursework in biostatistics, epidemiology and clinical trial design.

Ervin Epstein, M.D.

Co-Founder, Medical Advisor & Director

Ervin Epstein, M.D. is co-founder of PellePharm and serves on the PellePharm board of directors. Ervin is a practicing dermatologist. From 1972 to 2007, Ervin was a research dermatologist and clinical professor of dermatology at the University of California, San Francisco. Ervin and his colleagues conducted the first randomized trials evaluating chemoprevention of basal cell carcinomas, testing the effects of celecoxib, tazarotene and vismodegib in people with Gorlin syndrome.  His lab also identified dysregulated hedgehog signaling as the molecular defect causing all basal cell carcinomas. Ervin has served as secretary/treasurer and president of the Society for Investigative Dermatology and as a member of the advisory council of the National Institute for Arthritis, Musculoskeletal, and Skin Diseases of the NIH. He is an honorary member of investigative and clinical dermatologic societies worldwide. Ervin earned his M.D. from the University of California, San Francisco and his bachelor’s degree from Harvard University. He is lead author on papers that have appeared in the New England Journal of Medicine, Nature, and Science. From 2007 to 2018, Dr. Epstein was a scientist at the research arm of UCSF Benioff Children’s Hospital Oakland, an institute at the forefront of translating research into interventions for treating and preventing human diseases. At UCSF Benioff Children’s Hospital Oakland, Dr. Epstein’s research included the use of hedgehog inhibitors for the treatment of basal cell carcinoma and related conditions such as Gorlin syndrome.

Frank McCormick, Ph.D.

Co-Founder of BridgeBio

Frank McCormick, Ph.D., serves on the PellePharm board of directors. Frank is a professor and director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and co-founder of BridgeBio Pharma. Previously, Frank was co-founder and chief scientific officer of Onyx Pharmaceuticals, where he initiated and led drug discovery efforts leading to the approval of ONYX-015 in China for the treatment of nasophryngeal cancer. His group’s research also led to the identification of a CDK4 kinase inhibitor. Prior to Onyx, Frank worked with several Bay Area biotechnology companies, including Cetus Corporation, where he served as director of molecular biology and vice president of research, and Chiron Corporation, where he served as vice president of research. Frank is the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF, and has served as president for the American Association for Cancer Research (AACR). Currently, he oversees an NCI-supported national effort to develop therapies against Ras-driven cancers at the Frederick National Lab for Cancer Research. Frank earned his Ph.D. in biochemistry from the University of Cambridge and his bachelor’s degree in biochemistry from the University of Birmingham in England. He is a Fellow of the Royal Society. He is the author of over 285 scientific publications and holds 20 issued patents.

NEIL KUMAR, Ph.D.

Co-Founder of BridgeBio

Neil Kumar, Ph.D., serves on the PellePharm board of directors. Neil is the chief executive officer of Eidos Therapeutics and chief executive officer and co-founder of its parent company, BridgeBio Pharma. Prior to founding BridgeBio, he was a principal at Third Rock Ventures, where he supported and managed various portfolio companies and focused on new company formation and due diligence. Neil also served as interim vice president of business development and operations for MyoKardiam, Inc., a precision medicine company working on targeted therapies for the treatment of rare cardiovascular diseases. Previously, Neil served as an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead personalized medicine efforts. Neil was also involved in the formation of a gene chip company and was a technical consultant for AstraZeneca’s pathway signaling group. Neil earned his Ph.D. in chemical engineering from the Massachusetts Institute of Technology and holds bachelor’s and master’s degrees in chemical engineering from Stanford University. He is the author of several peer-reviewed papers in the fields of oncology and systems biology.

Anders Kronborg

CFO of LEO Pharma

Anders Kronborg serves on the PellePharm board of directors. Since 2015, Anders has been the CFO of LEO Pharma. Anders has over 20 years of senior financial and operations management experience, holding positions at Investment AB Kinnevik, Metro International, Danish commercial television station TV 2, Berlingske Tidend and DR, the Danish Broadcasting Corporation. Anders received a cand. polit. degree in Economics from the University of Copenhagen.

JEAN TANG, M.D., Ph.D.

Co-Founder, Medical Advisor & Director

Jean Tang, M.D., Ph.D. is co-founder of PellePharm and serves on the PellePharm board of directors. Jean is a practicing dermatologist and associate professor of dermatology at Stanford University. Her research focuses on finding new ways to treat and prevent non-melanoma skin cancer and genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. Jean and her colleagues discovered that hedgehog pathway inhibition could dramatically shrink basal cell carcinoma tumors in patients with Gorlin Syndrome in randomized clinical trials. She has led or co-led four investigator-initiated clinical trials, three of which were focused on basal cell carcinoma treatment or prevention. Jean earned both her M.D. and Ph.D. from Stanford University. She completed her dermatology residency at Stanford and later completed a three-year post-doctorate in mouse genetics at the University of California, San Francisco while simultaneously pursuing formal coursework in biostatistics, epidemiology and clinical trial design.

Ervin Epstein, M.D.

Co-Founder, Medical Advisor & Director

Ervin Epstein, M.D. is co-founder of PellePharm and serves on the PellePharm board of directors. Ervin is a practicing dermatologist. From 1972 to 2007, Ervin was a research dermatologist and clinical professor of dermatology at the University of California, San Francisco. Ervin and his colleagues conducted the first randomized trials evaluating chemoprevention of basal cell carcinomas, testing the effects of celecoxib, tazarotene and vismodegib in people with Gorlin syndrome.  His lab also identified dysregulated hedgehog signaling as the molecular defect causing all basal cell carcinomas. Ervin has served as secretary/treasurer and president of the Society for Investigative Dermatology and as a member of the advisory council of the National Institute for Arthritis, Musculoskeletal, and Skin Diseases of the NIH. He is an honorary member of investigative and clinical dermatologic societies worldwide. Ervin earned his M.D. from the University of California, San Francisco and his bachelor’s degree from Harvard University. He is lead author on papers that have appeared in the New England Journal of Medicine, Nature, and Science. From 2007 to 2018, Dr. Epstein was a scientist at the research arm of UCSF Benioff Children’s Hospital Oakland, an institute at the forefront of translating research into interventions for treating and preventing human diseases. At UCSF Benioff Children’s Hospital Oakland, Dr. Epstein’s research included the use of hedgehog inhibitors for the treatment of basal cell carcinoma and related conditions such as Gorlin syndrome.

Philip Beachy, Ph.D.

Co-Founder